Intuitive Surgical, Inc. (NASDAQ:ISRG) is MayTech Global Investments LLC's 10th Largest Position

MayTech Global Investments LLC raised its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 17.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 64,719 shares of the medical equipment provider's stock after purchasing an additional 9,380 shares during the period. Intuitive Surgical accounts for about 4.2% of MayTech Global Investments LLC's portfolio, making the stock its 10th biggest position. MayTech Global Investments LLC's holdings in Intuitive Surgical were worth $31,795,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA purchased a new position in shares of Intuitive Surgical during the third quarter valued at approximately $558,807,000. International Assets Investment Management LLC lifted its stake in shares of Intuitive Surgical by 49,383.6% during the 3rd quarter. International Assets Investment Management LLC now owns 1,090,619 shares of the medical equipment provider's stock worth $535,788,000 after acquiring an additional 1,088,415 shares during the last quarter. FMR LLC boosted its holdings in Intuitive Surgical by 8.3% during the 3rd quarter. FMR LLC now owns 10,971,085 shares of the medical equipment provider's stock valued at $5,389,765,000 after acquiring an additional 838,793 shares during the period. Strategic Financial Concepts LLC grew its position in Intuitive Surgical by 40,221.4% in the 2nd quarter. Strategic Financial Concepts LLC now owns 266,121 shares of the medical equipment provider's stock valued at $1,184,000 after acquiring an additional 265,461 shares during the last quarter. Finally, Manning & Napier Advisors LLC purchased a new stake in Intuitive Surgical in the second quarter worth $91,466,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 238 shares of the company's stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $477.50, for a total transaction of $113,645.00. Following the transaction, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,629,115. This represents a 4.14 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Jamie Samath sold 108 shares of the firm's stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $542.06, for a total transaction of $58,542.48. Following the completion of the transaction, the chief financial officer now directly owns 8,757 shares of the company's stock, valued at approximately $4,746,819.42. This represents a 1.22 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,459 shares of company stock worth $26,080,251. 0.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Evercore ISI reissued a "cautious" rating on shares of Intuitive Surgical in a research note on Friday, October 18th. The Goldman Sachs Group set a $604.00 price objective on shares of Intuitive Surgical in a research report on Friday, October 18th. Oppenheimer restated a "market perform" rating on shares of Intuitive Surgical in a research note on Friday, October 18th. JPMorgan Chase & Co. lifted their price target on shares of Intuitive Surgical from $495.00 to $575.00 and gave the company an "overweight" rating in a research note on Friday, October 11th. Finally, Raymond James raised their price objective on Intuitive Surgical from $500.00 to $540.00 and gave the stock an "outperform" rating in a report on Monday, October 14th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $526.06.

Intuitive Surgical Stock Down 0.7 %

Shares of Intuitive Surgical stock opened at $538.55 on Thursday. The company has a market cap of $191.82 billion, a P/E ratio of 86.58, a PEG ratio of 5.28 and a beta of 1.39. The firm's 50 day moving average price is $507.94 and its 200-day moving average price is $466.79. Intuitive Surgical, Inc. has a 52-week low of $304.50 and a 52-week high of $552.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.24 by $0.32. The business had revenue of $2.04 billion for the quarter, compared to the consensus estimate of $2.01 billion. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. As a group, equities research analysts forecast that Intuitive Surgical, Inc. will post 5.45 EPS for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.